| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/SCCAA.S8662 |
| P8608 | Fatcat ID | release_6e6ivvjpqzbtfloucv2rln7dte |
| P932 | PMC publication ID | 3781739 |
| P698 | PubMed publication ID | 24198520 |
| P50 | author | Lidia Cova | Q57008113 |
| P2093 | author name string | Vincenzo Silani | |
| P2860 | cites work | Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice | Q44472268 |
| Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. | Q44848574 | ||
| Specification of motoneurons from human embryonic stem cells. | Q45246951 | ||
| Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). | Q45970806 | ||
| Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). | Q46226347 | ||
| Amyotrophic lateral sclerosis linked to a novel SOD1 mutation with muscle mitochondrial dysfunction | Q46253711 | ||
| Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice | Q46254778 | ||
| Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. | Q46325370 | ||
| Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients | Q46621005 | ||
| Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells | Q46730802 | ||
| Olfactory ensheathing glia injections in Beijing: misleading patients with ALS. | Q47571840 | ||
| Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. | Q48146867 | ||
| Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. | Q48183466 | ||
| Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. | Q48199408 | ||
| Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis | Q48483204 | ||
| Human neural precursor cells continue to proliferate and exhibit low cell death after transplantation to the injured rat spinal cord | Q48655205 | ||
| Autologous olfactory ensheathing cell transplantation in human spinal cord injury | Q48735147 | ||
| Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model | Q24631645 | ||
| Stem cells in human neurodegenerative disorders--time for clinical translation? | Q27687068 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis | Q28215893 | ||
| Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis | Q28236796 | ||
| Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 | Q28236805 | ||
| Glutamate receptors: RNA editing and death of motor neurons | Q28247026 | ||
| RNA-protein interactions and control of mRNA stability in neurons | Q28248423 | ||
| Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons | Q28298056 | ||
| Induced pluripotent stem cells from a spinal muscular atrophy patient | Q29614340 | ||
| TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 | ||
| Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons | Q29616199 | ||
| Directed differentiation of embryonic stem cells into motor neurons | Q29616200 | ||
| Unraveling the mechanisms involved in motor neuron degeneration in ALS | Q29619073 | ||
| Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis | Q29619430 | ||
| Onset and progression in inherited ALS determined by motor neurons and microglia | Q29619515 | ||
| Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy | Q30483218 | ||
| Human embryonic stem cell-derived motor neurons expressing SOD1 mutants exhibit typical signs of motor neuron degeneration linked to ALS. | Q30486275 | ||
| Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats | Q30581117 | ||
| GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. | Q33292690 | ||
| Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. | Q33548806 | ||
| Progress toward the clinical application of patient-specific pluripotent stem cells | Q33559694 | ||
| A Drosophila model for TDP-43 proteinopathy | Q33733651 | ||
| Stem cell tracking by nanotechnologies | Q33848165 | ||
| Complex genetics of amyotrophic lateral sclerosis | Q33910597 | ||
| Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis | Q33919781 | ||
| Mutational analysis of TARDBP in neurodegenerative diseases | Q33927552 | ||
| Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). | Q34010341 | ||
| Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. | Q34044401 | ||
| Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells | Q34109542 | ||
| Nuclear factor TDP-43 can affect selected microRNA levels | Q34112413 | ||
| The skin in amyotrophic lateral sclerosis | Q34314425 | ||
| Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis | Q34568739 | ||
| Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model | Q34596280 | ||
| Transplanted mouse embryonic stem-cell-derived motoneurons form functional motor units and reduce muscle atrophy. | Q50612517 | ||
| Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. | Q50666206 | ||
| Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. | Q50790361 | ||
| Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. | Q51653840 | ||
| High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. | Q51815155 | ||
| Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. | Q51868850 | ||
| Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. | Q51986995 | ||
| Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis | Q57244961 | ||
| Motoneuron Transplantation Rescues the Phenotype of SMARD1 (Spinal Muscular Atrophy with Respiratory Distress Type 1) | Q61943890 | ||
| Skin abnormalities and autonomic involvement in the early stage of amyotrophic lateral sclerosis | Q72469137 | ||
| Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle | Q73053509 | ||
| Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis | Q73234498 | ||
| Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis | Q77669214 | ||
| Matrix metalloproteinases--a conceptional alternative for disease-modifying strategies in ALS/MND? | Q79814466 | ||
| Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis | Q79960014 | ||
| Dyslipidemia is a protective factor in amyotrophic lateral sclerosis | Q80503053 | ||
| Stem cell treatment in Amyotrophic Lateral Sclerosis | Q80507987 | ||
| Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS) | Q80856779 | ||
| Temporal response of neural progenitor cells to disease onset and progression in amyotrophic lateral sclerosis-like transgenic mice | Q81037241 | ||
| Stem-cell therapy in amyotrophic lateral sclerosis | Q81065129 | ||
| The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis | Q81277193 | ||
| Metalloproteinase alterations in the bone marrow of ALS patients | Q82595342 | ||
| The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice | Q82725703 | ||
| Feasibility of cell therapy for amyotrophic lateral sclerosis | Q82973966 | ||
| [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients] | Q83295447 | ||
| Human stem cells and drug screening: opportunities and challenges | Q83910679 | ||
| Stem cell renegades or pioneers? | Q84161552 | ||
| A surgical technique of spinal cord cell transplantation in amyotrophic lateral sclerosis | Q84520182 | ||
| Numerous FUS-positive inclusions in an elderly woman with motor neuron disease | Q84608229 | ||
| Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis | Q84612193 | ||
| Serum markers of type I collagen synthesis and degradation in amyotrophic lateral sclerosis | Q95811029 | ||
| Neurodegenerative disease-specific induced pluripotent stem cell research | Q37737385 | ||
| The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain | Q38312756 | ||
| TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration | Q38382616 | ||
| Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. | Q39311874 | ||
| Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. | Q39759649 | ||
| Prion-like disorders: blurring the divide between transmissibility and infectivity | Q39863503 | ||
| Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells | Q39910905 | ||
| Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation | Q39910909 | ||
| Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial | Q39955188 | ||
| Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis | Q40035096 | ||
| Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy | Q40151605 | ||
| Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats | Q40220494 | ||
| Recovery from paralysis in adult rats using embryonic stem cells. | Q40262579 | ||
| GDNF delivery using human neural progenitor cells in a rat model of ALS. | Q40425197 | ||
| Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis | Q40437067 | ||
| Functional properties of motoneurons derived from mouse embryonic stem cells. | Q40517622 | ||
| Altered expression of the glutamate transporter EAAT2b in neurological disease | Q40572506 | ||
| Neuropathology of ALS: an overview | Q41152629 | ||
| Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease | Q42188656 | ||
| Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects | Q42512822 | ||
| MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice | Q42722532 | ||
| Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis | Q42962080 | ||
| Neural precursor-derived astrocytes of wobbler mice induce apoptotic death of motor neurons through reduced glutamate uptake. | Q43014458 | ||
| Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein. | Q43028561 | ||
| Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)-bearing astrocytes | Q43163559 | ||
| Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. | Q43234179 | ||
| Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study | Q43513937 | ||
| Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model | Q43628011 | ||
| Cell therapy and stem cells in animal models of motor neuron disorders. | Q34693599 | ||
| Variation in the safety of induced pluripotent stem cell lines | Q34991636 | ||
| Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis | Q35094527 | ||
| Mice deficient in the ALS2 gene exhibit lymphopenia and abnormal hematopietic function. | Q35633071 | ||
| Stem-cell therapy for amyotrophic lateral sclerosis. | Q35832769 | ||
| Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. | Q35928006 | ||
| Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis | Q35987553 | ||
| Overlap between neurodegenerative disorders | Q36117422 | ||
| Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells | Q36158013 | ||
| Matrix metalloproteinases (MMPs) in health and disease: an overview | Q36348231 | ||
| Molecular biology of amyotrophic lateral sclerosis: insights from genetics | Q36573336 | ||
| The RNA-binding protein HuD: a regulator of neuronal differentiation, maintenance and plasticity | Q36574657 | ||
| Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. | Q36677109 | ||
| CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. | Q36899833 | ||
| Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. | Q36991962 | ||
| Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis | Q37105854 | ||
| Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics | Q37134134 | ||
| The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. | Q37254394 | ||
| Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules | Q37254921 | ||
| Research in motion: the enigma of Parkinson's disease pathology spread | Q37260288 | ||
| Is it too soon for mesenchymal stem cell trials in people with ALS? | Q37279972 | ||
| Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. | Q37290026 | ||
| Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry | Q37307371 | ||
| Cervical spinal cord therapeutics delivery: preclinical safety validation of a stabilized microinjection platform | Q37393215 | ||
| Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort | Q37393988 | ||
| Rethinking ALS: the FUS about TDP-43. | Q37419912 | ||
| Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. | Q37444336 | ||
| Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models | Q37455509 | ||
| MicroRNA and stem cell regulation. | Q37500194 | ||
| Stem cells in amyotrophic lateral sclerosis: state of the art. | Q37575591 | ||
| The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). | Q37617743 | ||
| Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice | Q37621803 | ||
| MicroRNA control of signal transduction | Q37706077 | ||
| Molecular pathways of frontotemporal lobar degeneration | Q37736479 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 145-156 | |
| P577 | publication date | 2010-10-27 | |
| P1433 | published in | Stem Cells and Cloning: advances and applications | Q15817523 |
| P1476 | title | Amyotrophic lateral sclerosis: applications of stem cells - an update | |
| P478 | volume | 3 |
| Q36861763 | Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells |
| Q34182540 | Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease |
| Q45845978 | NMR Metabolomics for Stem Cell type discrimination. |
Search more.